Company Analysis
Sign in

Oruka Therapeutics, Inc. (ORKA)

Nasdaq: ORKA · Pharmaceutical Preparations · Menlo Park, CA · filing with the SEC since 1997
Full chart Alerts Compare
Grade5.8
◀ Past 5.5● Present 5.4▶ Future 6.4
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2023, as filed
Revenue$0.00
Net income-$5.3M+46.2%
Earnings per share$-0.37+46.4%
Operating cash flow-$5.0M+54.1%
Cash$37.4M-11.8%
Debt$0.00
Shareholders’ equity$37.0M-11.2%
Shares, diluted14.4M+0.0%
Return on equity-22.3%
The recordfrom its filings
Filings in 2026112
Newest filingNov 12 · 144
Annual reportMar 12, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$340M
Insider buys, 12 months$0.00
Patents granted91
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$153MCash from operations -$124Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
15161718192021222325
As filed, in USD. Nothing here is a forecast.

News

Nov 9, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 26, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 20, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 15, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ORKA · research, not advice